ArriVent BioPharma (AVBP) Set to Announce Earnings on Monday

ArriVent BioPharma (NASDAQ:AVBP) is expected to release its Q3 2026 resultson Monday, November 16th. Analysts expect ArriVent BioPharma to post earnings of ($1.04) per share and revenue of $0.80 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 19, 2026 at 4:00 PM ET.

ArriVent BioPharma (NASDAQ:AVBP) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.06). On average, analysts expect ArriVent BioPharma to post ($4.04) EPS for the current fiscal year and ($3.48) EPS for the next fiscal year.

ArriVent BioPharma Price Performance

Shares of NASDAQ:AVBP opened at $13.64 on Monday. ArriVent BioPharma has a 12 month low of $11.36 and a 12 month high of $35.83. The stock has a market cap of $672.59 million, a price-to-earnings ratio of -3.77 and a beta of 1.66. The stock’s 50 day moving average price is $23.05 and its 200 day moving average price is $26.66.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Citigroup lowered their price target on ArriVent BioPharma from $40.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, October 7th. JonesTrading dropped their price objective on ArriVent BioPharma from $45.00 to $22.00 and set a “buy” rating on the stock in a research note on Wednesday, October 7th. Wall Street Zen upgraded ArriVent BioPharma from a “strong sell” rating to a “sell” rating in a report on Sunday, October 18th. Guggenheim upped their price objective on ArriVent BioPharma from $18.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, October 27th. Finally, B. Riley Financial decreased their target price on ArriVent BioPharma from $45.00 to $29.00 and set a “buy” rating for the company in a research note on Tuesday, October 20th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $24.56.

About ArriVent BioPharma

ArriVent BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing precision oncology therapies for patients with genetically defined cancers. The company’s primary focus is on targeted treatments for non-small cell lung cancer (NSCLC), particularly tumors driven by mutations in the epidermal growth factor receptor (EGFR) gene.

ArriVent’s lead product candidate is furmonertinib, an oral, irreversible EGFR tyrosine kinase inhibitor designed to target a range of EGFR mutations, including common mutations and exon 20 insertion mutations.